Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa

Next Previous
Search
Trial Profile

Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Tenofovir dipivoxil fumarate (Primary) ; Darunavir; Lamivudine; Ritonavir; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms iNADIAh; NADIA

    • Most Recent Events

    • 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
    • 22 Jul 2021 Results published in the New England Journal of Medicine
    • 10 Mar 2021 Primary endpoint (The percentage of patients with week-48 VL 400 copies/ml using FDA snapshot algorithm (non-inferiority margin 12%)) has been met as per the results presented at the 28th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top